高级检索
当前位置: 首页 > 详情页

m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Dept Gastroenterol, Tongji Hosp,Tongji Med Coll, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China
出处:
ISSN:

关键词: pancreatic cancer m(6)A tumor microenvironment immunotherapy mutation burden

摘要:
Recent studies have shown that RNA N-6-methyladenosine (m(6)A) modification plays an important part in tumorigenesis and immune-related biological processes. However, the comprehensive landscape of immune cell infiltration characteristics in the tumor microenvironment (TME) mediated by m(6)A methylation modification in pancreatic cancer has not yet been elucidated. Based on consensus clustering algorithm, we identified two m(6)A modification subtypes and then determined two m(6)A-related gene subtypes among 434 pancreatic cancer samples. The TME characteristics of the identified gene subtypes were highly consistent with the immune-hot phenotype and the immune-cold phenotype respectively. According to the m(6)A score extracted from the m(6)A-related signature genes, patients can be divided into high and low m(6)A score groups. The low score group displayed a better prognosis and relatively strong immune infiltration. Further analysis showed that low m(6)A score correlated with lower tumor mutation burden and PD-L1 expression, and indicated a better response to immunotherapy. In general, m(6)A methylation modification is closely related to the diversity and complexity of immune infiltration in TME. Evaluating the m(6)A modification pattern and immune infiltration characteristics of individual tumors can help deepen our understanding of the tumor microenvironment landscape and promote a more effective clinical practice of immunotherapy.</p>

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2019]版:
Q1 IMMUNOLOGY
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Dept Gastroenterol, Tongji Hosp,Tongji Med Coll, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Dept Gastroenterol, Tongji Hosp,Tongji Med Coll, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)